x

Posted 14 November, 2023

IMPEL PHARMACEUTICALS INC appointed Leonard S. Paolillo as new CEO

Nasdaq:IMPL appointed new Chief Executive Officer Leonard S. Paolillo in a 8-K filed on 14 November, 2023.


  As disclosed in the Form 8-K filed on November 2, 2023, effective as of November 4, 2023, Adrian Adams resigned as chairman of the Board and as President and Chief Executive Officer of Impel Pharmaceuticals Inc. (the "Company") and the Board of Directors (the "Board") of the Company appointed Leonard S. Paolillo, the Company's Chief Commercial Officer, as interim President and Chief Executive Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IMPEL PHARMACEUTICALS INC
Health Care/Life Sciences • Pharmaceuticals
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It engages in the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs with an initial focus on diseases of the central nervous system. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.
Market Cap
$182K
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. 


As disclosed in the Form 8-K filed on November 2, 2023, effective as of November 4, 2023, Adrian Adams resigned as chairman of the Board and as President and Chief Executive Officer of Impel Pharmaceuticals Inc. (the "Company") and the Board of Directors (the "Board") of the Company appointed Leonard S. Paolillo, the Company's Chief Commercial Officer, as interim President and Chief Executive Officer of the Company. 

In connection with his promotion to interim President and Chief Executive Officer of the Company, on November 7, 2023, the Company entered into an adjustment to Mr. Paolillo's compensation terms (the "Paolillo Compensation Adjustment"), including, among other things, that (i) Mr. Paolillo's annual base salary will be increased to $600,000 and (ii) an increase in Mr. Paolillo's interests under the Company's Management Incentive Plan (the "MIP") as described below. 

In addition, on November 7, 2023, the Company entered into an adjustment to the compensation terms (the "Kalb Compensation Adjustment" and, together with the Paolillo Compensation Adjustment, the "Compensation Adjustments") of Michael Kalb, the Company's Chief Financial Officer, including (i) a one-time $30,000 salary advance (the "Salary Advance"), subject to Mr. Kalb's continued employment until the earlier of (A) the closing of a Corporate Transaction (as defined in the MIP) or (B) December 31, 2023 and (ii) enabling Mr. Kalb to participate in the MIP. In the event that Mr. Kalb resigns for any reason prior to the earlier of (A) and (B), Mr. Kalb will be required to repay the entire Salary Advance. 

In connection with the Compensation Adjustments, the Company and certain of its lenders, including Oaktree Fund Administration, LLC ("Oaktree"), entered into a Letter Agreement, dated as of November 7, 2023, to, among other things, permit the Compensation Adjustments. 

Amended and Restated Management Incentive Plan 

As previously disclosed in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 7, 2023, on August 31, 2023, the Compensation Committee of the Board approved and the Company implemented, a Management Incentive Plan (the "MIP") for specified executive officers of the Company, including Mr. Paolillo and Mr. Adams, (collectively, the "MIP Officers") to incentivize and motivate the MIP Officers in the event of a Corporate Transaction (as defined therein). Under the MIP, in the event of a Corporate Transaction, 0.85% of the net cash consideration in such transaction was allocated to the MIP Officers. If any participating MIP Officer is no longer employed by the Company as of the closing of such Corporate Transaction, such MIP Officer's interest (such interest, "Forfeited Interest") under the MIP would be reallocated to the other remaining MIP Officers on a pro-rata basis. 

In connection with the resignation of Mr. Adams and the Compensation Adjustments, the Board approved an Amended and Restated MIP (the "A&R MIP") which permitted the Board to reallocate the Forfeited Interest in accordance with the Compensation Adjustments. 

The preceding summary description of the terms of the MIP applicable to the Company's executive officers is not complete and is qualified in its entirety by reference to the form of A&R MIP which is filed as Exhibit 10.1 hereto.